BMC Endocrine Disorders

Table 3 Laboratory results at baseline and week 52 in the treatment and comparative groups

From: Recombinant growth hormone therapy in children with Turner Syndrome in Korea: a phase III Randomized Trial

		Treatment group (N = 27)		Comparator (N = 31)
		N	Mean ± SD	N	Mean ± SD
ALT (IU/L)	Baseline	27	18.9 ± 14.4	31	20.4 ± 14.1
ALT (IU/L)	Week 52	26	18.3 ± 19.9	29	19.3 ± 16.9
AST (IU/L)	Baseline	27	30.4 ± 7.5	31	32.3 ± 7.2
AST (IU/L)	Week 52	26	28.2 ± 10.5	29	30.3 ± 13.0
ALP (IU/L)	Baseline	27	244.6 ± 164.2	31	274.0 ± 178.0
ALP (IU/L)	Week 52	26	298.0 ± 197.3	29	291.1 ± 162.6
Cholesterol (mg/dL)	Baseline	27	173.9 ± 26.8	31	170.7 ± 31.7
Cholesterol (mg/dL)	Week 52	26	166.9 ± 21.2	29	160.6 ± 22.5
Triglyceride (mg/dL)	Baseline	27	89.5 ± 61.6	31	119.9 ± 70.3
Triglyceride (mg/dL)	Week 52	26	99.5 ± 48.8	29	116.3 ± 89.0
Hemoglobin A1c (%)	Baseline	27	5.01 ± 0.44	31	5.17 ± 0.35
Hemoglobin A1c (%)	Week 52	26	5.17 ± 0.45	29	5.32 ± 0.27
TSH (uIU/mL)	Baseline	27	3.06 ± 1.51	31	3.13 ± 1.65
TSH (uIU/mL)	Week 52	26	2.81 ± 1.62	29	3.14 ± 2.16
Free T4 (ng/ dL)	Baseline	27	1.39 ± 0.27	31	1.37 ± 0.20
Free T4 (ng/ dL)	Week 52	26	1.36 ± 0.24	29	1.35 ± 0.18

Back to article page

ISSN: 1472-6823

Contact us

General enquiries: journalsubmissions@springernature.com